Cutting-edge artificial intelligence and machine learning applications are accelerating discoveries in cancer biomarker identification and drug combination prediction. Multi-omics integration platforms like the Molecular Twin enable precise stratification of complex diseases such as pancreatic adenocarcinoma by analyzing genomic, transcriptomic, proteomic, and metabolomic data collectively. Additionally, AI models that incorporate protein structural data are emerging to predict synergistic drug interactions, heralding a new era in precision medicine. Tech firms and academic collaborations continue to push computational boundaries to transform translational research and therapeutic design.